Clinical Trial Update: Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ramelteon sublingual for acute depressive episodes in adults with bipolar I disorder was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ramelteon Sublingual (ramelteon)

Snippet

Sponsor: Takeda | Conditions: Acute Depressive Episode | Phase 3 | Status: TERMINATED | Results posted: 2016-05-16